0% found this document useful (0 votes)
50 views37 pages

Practice of Pharmacy: Prepared By: Jelly Mae T. Oviedo, RPH

This document provides an overview of clinical pharmacy and related topics. It discusses the roles and responsibilities of clinical pharmacists in providing patient care and pharmaceutical care. It also covers topics like evidenced-based medicine, drug development process, pharmacoepidemiology study designs, clinical pharmacy services, therapeutic drug monitoring, and hospital pharmacy classifications.

Uploaded by

Nica Chua
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
50 views37 pages

Practice of Pharmacy: Prepared By: Jelly Mae T. Oviedo, RPH

This document provides an overview of clinical pharmacy and related topics. It discusses the roles and responsibilities of clinical pharmacists in providing patient care and pharmaceutical care. It also covers topics like evidenced-based medicine, drug development process, pharmacoepidemiology study designs, clinical pharmacy services, therapeutic drug monitoring, and hospital pharmacy classifications.

Uploaded by

Nica Chua
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 37

PRACTICE OF

PHARMACY

Prepared by: Jelly mae t. Oviedo, rpH


Clinical Pharmacy

- branch of pharmacy where the pharmacist provides patient care that optimizes the use
of medications and promotes health, wellness and disease prevention.
Clinical pharmacist
• Interact with the health care team
• Interview and assess the patient information
• Design and implement a therapeutic plan
• Make therapeutic recommendation
• Monitor Patient’s response to therapy
• Provide drug information
Pharmaceutical care
- is the responsible provision of drug therapy for the purpose of achieving definite
outcomes that improve a patient’s QOL
-A patient-centered practice
Major Functions of Pharmaceutical Care:
• Identifying potential and actual drug-related problems
• Resolving actual drug-related problems
• Preventing potential drug-related problems
Pharmaceutical care
Expected Outcomes:
• Cure a disease
• Elimination or reduction of patient’s symptoms
• Arresting or slowing the disease process
• Preventing disease and symptoms
Parts of a Prescription
Incorrect Prescription (DOH AO no. 62)
Erroneous:
• BN preceded GN ex. (Lipitor) Atorvastatin
• GN is in parenthesis ex. (Atorvastatin) Lipitor
• BN is not in parenthesis ex. Atorvastatin Lipitor
Violative
• GN is not written
• BN is written, GN is not written legibly
• Terms that hinder Generic dispensing
Impossible
• Only GN is written (not legible)
• GN does not correspond to the BN
• Both GN and BN are written, but not legible
Note:
• Erroneous prescription should be filled, kept and reported to nearest DOH.
• Violative and Impossible prescriptions should not be filled but kept, and
reported to the nearest DOH
• In Violative and Impossible prescriptions, ask the patient to return to
prescriber to get proper prescription.
Evidenced-based Medicine (EBM)

-The conscientious, explicit and judicious use of current best evidence in


making decisions about the care of the individual patient.
Heirarchy of Evidence:
• Systematic Reviews
• Randomized Clinical Trials
• Non-Randomized Trials
• Observational Studies
• Expert Opinions
Drug Information sources:
Primary Source
• Provide the most current information
• Ex. Journal Articles
Secondary Source
• For quick and selective screening of the primary literature
• Ex. Abstracting and Indexing Services
Tertiary Sources
• Provide easy and convenient access: information may be outdated
• Ex. Textbooks
DRUG DEVELOPMENT
Pre-Clinical Stage Animal Studies

Assess safety in healthy human volunteers


Phase 1 (Screening for Safety)
(20-100)

Evaluate effectiveness of drugs in patients with disease or


condition
II-a Identification of doses
Phase 2 (Establishing the Test Protocol) II-b Assess efficacy
(100-300)
-Double Blinded Randomized Clinical Trials

Large-scale multicenter clinical studies


-Confirmation of doses
-Expanded tolerability profile
Phase 3 (Final Testing)
Benefit-risk ration
(100-3000)
-Double Blinded Randomized Clinical Trials

Phase 4 (Post Marketing) Post-marketing studies


-Detect previously unknown AE and DI
PHARMACOEPIDEMIOLOGY STUDY DESIGN

• - study of use and effects of drugs in a large population


Case Report
- About a single case or a series of related cases
Cross- sectional Study
- Prevalence studies
- Survey the population at single point in time
Case-control Study
- Retrospective Study
- Observational study
- Samples chosen based on presence or absence of cases
- Information recollected about risk factors
- Advantage: Inexpensive
- Disadvantage: Recall bias
Cohort Study
• Prospective or Retrospective follow up Study
• Observational study
• Samples chosen based on presence or absence of risk factors
• Subjects are followed over time for development of disease
• Advantage: Inexpensive
• Disadvantage: Recall bias
Randomized Controlled Clinical Trial
• Gold Standard in assessing effects of drugs
• Experimental Study Design-intervention
• Randomization
• Advantages: Decreases/ reduces bias Disadvantages: Expensive, time-consuming
• Eliminates confounding factors Ethical considerations
Clinical Pharmacy Services

Patient Record/ Databases


1. Medical History
General Patient Information- name, sex, etc.
Chief complaint (CC)- reason for seeking medical care
History of Present Illness (HPI)- narrative that describes the patient’s current medical problem
Past Medical History (PMH)- brief description of current and previous medical conditions that
may or may not be related to present illness
Personal/ Social History/ Lifestyle – diet, use of tobacco, alcohol drinking habits, illicit drugs
Family Medical History (FMH)- medical history of the patient’s first degree relative
Medication History- current and past medication, OTC drugs, ADR, compliance
Review of System- Patient’s complaint not included in the HPI
Pharmacogenomics Studies

• -comparing value of drug or therapy with another


1. Cost of Illness (COI)- measure of cost attribute to a specific disease
• Direct Medical Costs- related to the therapy ex. Drug, insulin, syringe
• Indirect Medical Costs- not related to the therapy ex. Fare, loss in productivity
• Direct Non-medical Costs- ex. Salary of the health care professional

2. Cost Benefit Analysis (CBA)- identify and measure all the costs in providing treatment and comparing with the benefits to the
result.
3. Cost Minimization Analysis (CMA)- compare two or more treatment with the same therapeutic oiutcome, / look for the
treatment with the lowest possible cost

4. Cost Utility Analysis (CUA)- assess the perceived mental, physical and general functioning of the patrient / Integrates
patient’s QALY (physical, social and emotional aspect of patient’s well-being)
Ex. Chronic diseases- maintenance (Integrates patient preference in health related decisions
Therapeutic Drug Monitoring

• Encompasses the measurement of serum drug levels and the


application of clinical pharmacokinetics to improve patient care.
• Determination of plasma concentration of drugs to adjust therapy
• Optimizes individual drug therapy
• Maintain the drug concentration in the blood
• Trough Level- lowest drug level in the body
• Peak Level- highest drug level in the body
Patient Medication Counselling

• QUESTIONS:
Close –narrow
-used when direct answer is needed
-answerable by Yes or No
-decreased quality and quantity of information
-decreased opportunity to develop rapport with the patient
Open – wide-ranging
-not directly answerable by Yes or No
- increased quality and quantity of information
-can develop rapport, assess disposition of the patient
Leading- usually closed
• -contqain their own answer
• -imply judgement on the patient
• Not fruitful
• Must be avoided
Double or Multiple
• -presents the patient with two or more inquiries at the same time
• -traps the patient in a barriage of questions
• -patients get confused, irritated
Preventive Model:
• Primary Level of Prevention
• - is concerned to prevent onset of disease and reduce incidence
• Secondary Level of Prevention
• -is concerned to prevent development of existing disease, minimize its severity, reverse its progress
and reduce prevalence
• Tertiary Level of Prevention
• -is concerned to prevent deterioration, relapse, and complications, promote rehabilitation and help
adjust to terminal conditions
HOSPITAL PHARMACY

• -is an organized structure which pools together all the health professionals, the diagnostic and
therapeutic facilities, equipment and delivering health care to the public
• Jonathan Roberts – Father of Hospital Pharmacy

Functions:
• Patient care(pay or charity)
• Education
• Research
• Public Health
• Classifications:
A. Type of Service
General
• patient with any type of illness
• Atleast 6-bed capacity for 24 hours admission
Special
• Address special condition
• With specialized clinical services
• Ex. San Lazaro – Infectious diseases
• Heart center- cardiovascular cases
• NICI- renal and neurologic cases
Long Term Health Care Facility
• Continuous nursing services
• Medical care to individuals needing long term healthcare
• Resident Treatment Facility
• Regular and emergency health services and supportive services
Integrated Heath Care
• Hospitals merged with other hospitals and other patient care services like home health
care, long term and wellness facilities
Clinic
• Facility or area where ambulatory patients are seen for special study, appointments and
treatment by a group of physcians practicing together, and where the patient is not
confined in the hospital
B. Length of Stay:
• Short term- less than 30 days
• Long term- more than 30 days
C. Ownership
• Governmental
• Non-governmental
D. Bed Capacity
• By 50’s
• E. Levels of Services
1. Primary
• Primary medical use
• For providing emergency care and hospitalization in simple cases
2. Secondary
• Primary level with surgical care or specialization
• Experties of physicians with not less than 6 months training
• Departmentalized
• Tertiary
• Secondary level with sub specialization
• Teaching hospital
• Tertiary Level 1- for cases requiring sophisticated diagnostic
• Tertiary Level 2- has training and research capabilities/ provides residency training programs
• Tertiary Level 3- with teaching , training, and research functions
• Tertiary Level 4- expensive and sophisticated diagnostic
• Provincial- Provides tertiary level 1
• Regional- Provides tertiary level 2
• Medical Center- Provides tertiary level 3
• District- front-line hospital: secondary medical care
DIAGNOSTIC LABORATORY
EXAMINATION

• Creatinine kinase (CK)


• CK-MM- Skeletal muscles
• CK-MB- Heart
• CK-BB- Brain
- Aid in the diagnosis of myocardial or skeletal muscle damage
DIAGNOSTIC LABORATORY
EXAMINATION

• Lactate Dehydrogenase
• LDH1 and LDH2- Heart
• LDH3 – Lungs
• LDH-4 and LDH5- Liver and skeletal muscles

- Aid in diagnosing MI, hepatic disease, and lung disease


DIAGNOSTIC LABORATORY
EXAMINATION

• Akaline phosphatase (ALP)


• IF increased, biliary obstruction, Paget’s disease, osteomalacia,
hyperparathyroidism
DIAGNOSTIC LABORATORY EXAMINATION

• Alanine aminotransferase (ALT)


• AKA Serum Glutamic-Pyruvic Transaminase (SGPT)
• Relatively specific for liver cells
• If increased, there is acute myocardial Infarction

• Aspartate aminotransferase (AST)


• AKA Serum Glutamic-oxaloacetic transaminase (SGOT)
• If increased, there is acute hepatitis
• If super increased, there is liver cirrhosis and fatty liver
DIAGNOSTIC LABORATORY
EXAMINATION
• Cardiac Troponins
• Troponin T: Cardiac and skeletal muscle
• Troponin I: Cardiac muscles
• Troponin C: Skeletal and cardiac muscles

• - Diagnosis of MI
COMMON RENAL FUNCTIONS

• Blood Urea Nitrogen (BUN)


• End product of protein metabolism
• If increased, there is renal disease
• If decreased, there is liver disease

• Creatinine
• Metabolic breakdown product of muscle creatine phosphatase
• If increased, there is renal failure
COMMON RENAL FUNCTIONS

• Creatinine Clearance
• The rate at which creatinine is removed from the blood by the kidneys
• Normal Creatinine clearance is 80-120mL/ min
• If decreased, there is renal failure

• Remember the Formula?


Electrolytes

• Sodium
• If increased, hypertension
• Potassium
• If increased, renal dysfunction
• If increased, muscle weakness
• Chloride
• If increased, there is acute renal failure, renal tubular acidosis, primary
hyperparathyroidism, dehydration
• If decreased, there is chronic renal failure, adrenal insufficiency
Minerals

• Calcium
• If increased, hyperparathyroidism, caused by increased diuretic use (Thiazide)
• If decreased, PTH or Vitamin D deficiency, caused by increased diuretic use (Loop)and osteoporosis
• Magnesium
• If increased, there is Addison’s disease
• If decreased, caused by severe diarrhea, hyperaldosteronism, and diuretic use
• Phosphate
• If increased, there is renal dysfunction, increased vitamin D intake
• If decreased, there is insufficient vitamin D intake
Vitamin and Mineral Deficiencies

Calcium Osteoprosis
Iron Anemia
Potassium Hypokalemia
Zinc Parakeratosis
Vitamin C Scurvy
Vitamin D Rickets
Vitamin B1 Beriberi
Vitamin B3 Pellagra
Drugs to avoid in Pregnancy

• Sulfonamides
• Kernicterus (bilirubin in CNS)
• Aminoglycosides (Ototoxicity, damage to CN 8
• Fluoroquinolones
• Abnormal cartilage development
• Tetracyclines
• Discolored teeth
• Chloramphenicol
• Gray Baby Syndrome
Drugs to avoid in Pregnancy

• Thalidomide
• Phocomelia (short)
• Amelia (None)
• Meromelia (Fused)
• Ace Inhibitors
• Renal dysgenesis
• Phenytoin
• Fetal hydantoin syndrome
Drugs to avoid in Pregnancy

• Lithium
• Ebstein Anomaly
• NSAIDS
• Premature Closing of the PDA (Patent Ductus Arteriosus
• Decreased PGE, maintains the patency of ductus arteriosus
• Diethylstilbestrol
• Vaginal adenocarcinoma upon adolescence

You might also like